Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONEÂ® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONEÂ® 20 mg